Vitamin B5 may treat psoriasis and other “autoimmune” conditions

As the readers know, vitamin B5 is the precursor of Coenzyme-A (CoA) – a crucial component of the Krebs Cycle, without which not only does the Krebs Cycle malfunctions, but may also affect the activity of the enzyme pyruvate dehydrogenase (PDH), which feeds pyruvate into the Krebs Cycle in the form of acetyl-CoA. So, low levels of vitamin B5 translate into low levels of CoA, and thus low rate of pyruvate metabolism through the oxidative pathway. For many years, vitamin B5 has been of interest mostly to scientists working on so-called “mitochondrial conditions”, which to this date are claimed to be very rare and mostly of genetic origin. Yet, the study below shows that supplementing vitamin B5 is therapeutic in a condition, which medicine continues to claim has nothing to do with metabolism/mitochondria, but is simply a chronic inflammatory disorder of “unknown etiology”, yet (of course) largely genetically driven. Crucially, the study demonstrated the beneficial effect of N5 both in-vitro and in humans. The form of B5 used in the study was pantethine, and while I can’t get access to the full study yet, most human trials use for lowering cholesterol with this form of B5 used 600mg-900mg daily. And last but not least, as the study itself states, the anti-inflammatory effect of B5 seen in this study with psoriasis should translate into other “autoimmune” conditions as well, given their shared origin. In fact, there has been a recent regulatory push to merge all the separate “autoimmune” conditions into a single “autoimmune” spectrum and then each individual former condition would be re-labelled as a “localized symptom” of the spectrum. In other words, medicine itself is pushing for a change in naming convention so that psoriasis and, say, lupus, or rheumatoid arthritis (RA), or multiple sclerosis are considered a single condition, but with symptoms localized to specific organs/tissues. Namely, psoriasis becomes a skin symptom and RA becomes a joint symptom of the same systemic “autoimmune” condition. This recent push is mostly for economic reasons, as Big Pharma would like to “re-purpose” drugs approved for a specific “autoimmune” condition to be applicable/indicated for all other “autoimmune” conditions without the need to do a hugely expensive and slow separate clinical trial with a specific drug for each separate “autoimmune” condition. In any event, my point is that medicine itself is now saying that virtually all “autoimmune” conditions are one and the same, which strongly suggests that the findings of this study about B5 in psoriasis should apply to all other “autoimmune” conditions as well.

http://dx.doi.org/10.1084/jem.20252558

 

Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial

“…Dendritic cells are specialized immune cells that help to coordinate the different parts of the immune system. They can engulf and present foreign antigens to activate highly specific T cells, as well as secrete a variety of immune signaling molecules to recruit other types of immune cells and promote inflammation. Because of this central role in directing immune responses, abnormal activation of dendritic cells is thought to underlie a variety of autoimmune diseases, including psoriasis. “Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target,” the authors wrote. “Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored.” Zhang further added, “Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression. But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored.”

“…Through their study the team showed that depleting these enzymes inhibited dendritic cell activation and limited their ability to activate T cells. Moreover, treating mice with a drug that inhibits Vanins prevented the animals from developing psoriasis.”

“…Zhang and colleagues determined that increased Vanin activity in dendritic cells reduces panthetine levels, leading to increased cholesterol synthesis and dendritic cell hyperactivation. Replenishing pantethine levels reversed this process, lowering the accumulation of cholesterol and suppressing dendritic cell activation. “Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation,” they wrote.”

“…“We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the upregulation of Vanins,” Zhang noted.

To investigate further the researchers initiated a small-scale trial of pantethine supplementation in 24 human psoriasis patients. Every patient was treated with topical calcipotriene/betamethasone ointment, but half of the patients also received oral pantethine. Over the course of 12 weeks, patients given the additional pantethine treatment showed improved symptoms, particularly if they had elevated blood cholesterol levels at the start of the trial. “Importantly, our clinical trial revealed that pantethine combination therapy significantly decelerates the progression of psoriasis in patients,” they reported.”

Author: haidut